Oropharynx inflammation; gingivitis, stomatitis, pharyngitis; in dentistry after tooth extraction.
active substance: benzydamine;
1 ml of solution contains 1.5 mg of benzydamine hydrochloride;
Excipients: ethanol 96%, glycerin, methylparaben (E 218), saccharin sodium, sodium bicarbonate, polysorbate 20, mint flavor, quinoline yellow 70% (E 104), blue patented V (E 131), purified water.
Main physical and chemical properties: transparent green liquid with a characteristic odor of mint.
Means for application in dentistry. Other means for topical use in the oral cavity.
ATX code A01A D02.
Benzidamine is a non-steroidal anti-inflammatory drug (NSAID) with analgesic and anti-exudative properties.
In clinical trials, benzydamine has been shown to be effective in relieving the symptoms that accompany localized irritating pathological processes in the mouth and pharynx. In addition, benzydamine has anti-inflammatory and local analgesic effects on the oral mucosa.
The fact of absorption through the mucous membrane of the oral cavity and pharynx was proved by the presence of measurable amounts of benzydamine in human blood plasma. However, this is not sufficient to have any systemic pharmacological effect. Excretion occurs mainly in the urine, mainly in the form of inactive metabolites or conjugated compounds.
It has been shown that when applied topically, the accumulation of an effective concentration of benzydamine in inflamed tissues is achieved due to its ability to penetrate the mucous membrane.
Symptomatic treatment of irritation and inflammation of the oropharynx; pain caused by gingivitis, stomatitis, pharyngitis; in dentistry used after tooth extraction or for prophylactic purposes.
Hypersensitivity to the active substance or other components of the drug.
Interaction with other drugs and other types of interactions.
Interaction studies have not been performed.
Features of application.
If you develop sensitivity with prolonged use, you should stop treatment and consult a doctor to prescribe appropriate treatment.
In some patients, ulcers of the mucous membranes of the cheeks / pharynx can be caused by serious pathological processes. Therefore, patients whose symptoms have worsened or not decreased within 3 days or who have a fever or other symptoms should consult a physician or dentist as appropriate.
Benzidamine is not recommended for use in patients with hypersensitivity to acetylsalicylic acid or other non-steroidal anti-inflammatory drugs.
The drug can cause bronchospasm in patients with bronchial asthma or a history of bronchial asthma. Such patients must be warned.
For athletes: the use of drugs containing ethyl alcohol may give a positive anti-doping test result.
Use during pregnancy or breastfeeding
There are no adequate data from the use of benzydamine in pregnant or breast-feeding women. The ability of this drug to penetrate into breast milk has not been studied. There are insufficient data from animal studies to draw any conclusions about the effects of this product during pregnancy and breastfeeding. The potential risk for humans is unknown.
Zipelor should not be used during pregnancy or breastfeeding.
Ability to influence the speed of reaction when driving a car or other mechanisms.
When used in the recommended doses, the drug has no effect on the ability to drive and use machines.
Method of application and dose
Measure 15 ml of Zipelor solution from the vial using a measuring cup and rinse the mouth with undiluted or diluted (15 ml of solution can be diluted with 15 ml of water) preparation. Rinses should be performed 2-3 times a day. Do not exceed the recommended dose.
The drug should not be used in children under 12 years due to the possibility of swallowing the solution while rinsing the mouth.
There have been no reports of topical benzidamine overdose.
However, it is known that benzydamine when ingested in large doses (which is hundreds of times higher than possible doses of this dosage form), especially in children, can cause agitation, convulsions, tremor, nausea, sweating, ataxia, vomiting. Such an acute overdose requires immediate gastric lavage, treatment of water-electrolyte imbalance and symptomatic treatment, adequate hydration.
Adverse reactions are ranked under headings of frequency: very common (≥ 1/10); often (≥ 1/100 to <1/10); uncommon (≥ 1/1000 to <1/100); rare (≥ 1 / 10,000 to <1 / 1,000); very rare (<1 / 10,000); frequency unknown (cannot be estimated from the available data).
In each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
From the gastrointestinal tract: rarely – burning sensation in the mouth, dry mouth; frequency unknown – hypoesthesia of the oral cavity, nausea, vomiting, edema and discoloration of the tongue, discoloration.
From the immune system: rarely – hypersensitivity reaction; frequency unknown – anaphylactic reaction.
From the respiratory system, chest and mediastinum: very rarely – laryngospasm; frequency unknown – bronchospasm.
From the skin and subcutaneous tissue: infrequently – photosensitivity; very rarely – angioneurotic edema; frequency unknown – rash, itching, hives.
From the nervous system: frequency unknown – dizziness, headache.
Do not use the drug after the expiration date indicated on the package.
Store in the original package at a temperature not exceeding 25 ºC.
Keep out of reach of children.
100 ml in a bottle. 1 vial in a pack.